We have developed non-invasive, accessible genomic tools to identify underlying neurodegenerative disease pathologies, drug response, progression rate, and tools to facilitate on-target enrollment for Phase 2 and 3 clinical trials.
Location: United States, California, San Diego
Member count: 1-10
Investors 2
| Date | Name | Website |
| - | Creative D... | creativede... |
| - | Crescent R... | crescentri... |